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ABSTRACT
Apolipoprotein B is More Strongly Associated with Cardiovascular Risk Factors than LowDensity Lipoprotein Cholesterol in Young-to-Middle Aged Adults
By
Aniqa Alam
December 11, 2017

Cardiovascular disease (CVD) is the leading cause of death in the United States. Medical
practitioners and public health officials alike consider atherosclerosis, in which plaque buildup
leads to the hardening of arteries, to be one of the main culprits in CVD morbidity and
mortality. Measuring low-density lipoprotein cholesterol (LDL-C) has been touted as an
effective proxy for assessing the risk for atherosclerosis. However, new emerging evidence
show that traditional lipid biomarkers, such as LDL-C, may not be as robust in CVD prediction as
previously thought. Apolipoproteins, which are involved in the creation of lipoproteins, have
been shown to be effective predictors of CVD events, even more so than LDL-C in some cases,
but previous research have also established a non-linear trend with apolipoprotein B (ApoB)
distribution when age is involved. Therefore, in light of past research, this study aims to
examine potential differential associations between ApoB, LDL-C, and cardiovascular risk
factors in the context of age groups. Using the 2013-2014 cycle of the National Health and
Nutrition Examination Survey, we observed Spearman correlations and Wilcoxon/Kruskal-Wallis
scores between various CVD risk factors (e.g.: body mass index, hypertension, diabetes status,
etc.) and ApoB and LDL-C across two age cohorts. We found that ApoB has a special
relationship with the younger cohort that does not manifest with LDL-C, and that this
relationship attenuates in the older cohort. Based off of these results along with previous
studies, assessment of CVD risk among the young would benefit from including ApoB in the
already established battery of biomarkers.
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Introduction
Cardiovascular disease (CVD) is the leading cause of death in the United States (Gu, PauloseRam, Burt, & Kit, 2014) and according to the American Heart Association one American will die of a
coronary event every 1 minute and 23 seconds (Go et al., 2014). Medical practitioners and public health
officials alike consider atherosclerosis, in which plaque buildup leads to the hardening of arteries, to be
one of the main culprits in CVD morbidity and mortality (Singh, Mengi, Xu, Arneja, & Dhalla, 2002).
Measuring low-density lipoprotein cholesterol (LDL-C) has been touted as an effective proxy for
assessing the risk for atherosclerosis. However, new emerging evidence show that traditional lipid
biomarkers, such as LDL-C, may not be as robust in CVD prediction as previously thought (Chan & Watts,
2006). This lack of sensitivity in CVD prediction is especially concerning when considering that statins
and other medications are often the first lines of defense in attempting to reduce the risk of
atherosclerosis by targeting LDL-C (Riccioni and Sblendorio, 2012). From 2011 to 2012, nearly 28%
percent of adults over the age of 40 admitted to using lipid-lowering medication (Gu, Paulose-Ram, Burt,
& Kit, 2014). If LDL-C's sensitivity in predicting CVD events is not effective as previously believed, then
focusing mainly on LDL-C may not be assessing the true risk of atherosclerosis and CVD. Nontraditional
biomarkers need to be investigated in order to improve sensitivity in CVD prediction. One such class of
nontraditional biomarkers to be considered are apolipoproteins.
Apolipoproteins are a family of proteins involved in the synthesis of lipoproteins, which
transport lipids such as cholesterol and triglycerides through circulation (Feingold & Grunfeld, 2000).
They are crucial to the formation of various forms of cholesterol-carrying lipoprotein particles, including
LDL-C and high-density lipoprotein cholesterol (HDL-C). Apolipoprotein B (ApoB) in particular has been
shown to be associated with atherosclerosis and atherosclerotic heart disease events and may be an
even better predictor of CVD events than traditional LDL-C counts (Gigante et al., 2012; Lamarche et al.,
1996). Many of our recommendations in the health care system concerned with reducing cardiovascular
risk are based on our understanding that atherosclerotic risk is tied uniquely to LDL-C. In recent
literature, however, ApoB has been increasingly shown to be associated with cardiovascular risk, even
more so than LDL-C (Sniderman, Islam, Yusuf, & McQueen, 2013). ApoB has also been shown to be
associated with carotid atherosclerosis (Steffen et al., 2017) and with coronary artery calcification in
young adults (Wilkins, Li, Sniderman, Chan, & Lloyd-Jones, 2016).
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Age is a major factor in the incidence of CVD events. Advanced age in particular has been proven
to be significantly associated with heart disease (Castelli, 1984), but youth is not always protective in
terms of cardiovascular risk. In fact, in a landmark study by Enos, Holmes, and Beyer (1951), autopsies
performed on 300 United States soldiers killed during the Korean War showed subclinical
atherosclerosis among those in their late teens and early adulthood. Subclinical atherosclerosis in the
young with metabolic syndrome can often be a sign of premature heart disease (Tzou et al., 2005), and
as global population trends sway more towards metabolic dysfunction (Go et al., 2014), it seems all the
more pertinent to focus preventative interventions in young adulthood as well as retirement age.
Bachorik, Lovejoy, Carroll, and Johnson (1997) examined the third national health and nutrition
examination survey (NHANES III) conducted between 1988 and 1991. They aimed to examine the
distribution of apolipoprotein B and A1 among men and women in the United States and found that
ApoB largely followed LDL-C distribution throughout age, but increasingly diverged in older age. Among
men, Bachorik and colleagues (1997) found an overall trend of increasing median ApoB levels as age
progressed, followed by a plateau in middle-age, ending with a decrease in old age. In women, this
pattern was also evident, but was modified with two plateau periods: one in early adulthood and
another in post-menopausal stage. Building off of these conclusions and other previous research, this
study aims to examine potential differential associations between ApoB, LDL-C, and cardiovascular risk
factors in the context of age groups.

Methods
To examine the relationship between ApoB and CVD risk factors versus LDL-C and CVD risk
factors, we utilized NHANES from the 2013-2014 cycle. At the time of analysis, this was the most recent
iteration of the survey available. NHANES employs a complex sampling strategy to represent the
American population as a whole. However, for the purposes of this study, we did not require nationally
representative data, and therefore, did not apply weights. Rather, the aim was to examine serum ApoB
and LDL levels within the same individual, and explore the influence of age on the relationship between
these biomarkers and CVD risk factors.
The total population of NHANES 2013-2014 consists of 10,175 individuals, with 6,261 being
between the ages of 17 and 80 years. The study cohort was divided into two age groups: those aged 1850 and 51-80. The cutoff point between the two age groups was chosen based off of the findings of
Bachorik and colleagues (1997), in which they found menopause-induced hormone changes to be the
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cause of the double plateau in women. Variables of interest included gender, race, body mass index
(BMI), socioeconomic status, high-density lipoprotein cholesterol (HDL-C), triglycerides, diabetes status,
blood pressure, and smoking status.
Serum ApoB, LDL-C, HDL-C, and triglyceride measurements were derived from venipuncture
samples collected on mobile examination centers. Measurements for serum ApoB, LDL-C, and
triglycerides are only available if participants were 12 years and above and were examined in the
morning. HDL-C measurements were available for those aged 6 years and above. NHANES set a reported
age cutoff as 80, with those above the age of 80 being entered into the system as “80”. BMI was
calculated as weight in kilograms divided by height in meters-squared. Data on income-to-poverty was
available and used as a proxy for socioeconomic status, along with educational status. The income-topoverty ratio (ItPR) was calculated by dividing household family income by the state-established poverty
guidelines. Values were not reported if the reported income was less than or equal to $20,000, and the
cutoff point was at a ratio of 5.00. Race was split into four levels: non-Hispanic black, non-Hispanic
white, Mexican-American, and “Other”. The category “Other” consists of all races not previously named,
including Asian. For the purpose of analysis, diabetes status was coded dichotomously. Diabetes was
confirmed if the participants reported “yes” to the question “Have you ever been told by a doctor or
health professional that you diabetes or sugar diabetes?” and/or if they were found to have blood
glycohemoglobin levels of 6.5% and above. Blood glycohemoglobin measurements were also collected
from mobile examination centers. Smoking status was confirmed if participants answered “Yes” to at
least one of the following questions: “Have you smoked at least 100 cigarettes in your entire life?”, “Do
you now smoke cigarettes?”, “During the past 5 days, including today, did you smoke cigarettes, pipes,
cigars, little cigars or cigarillos, water pipes, hookahs, or e-cigarettes?”, and “During the past 5 days,
including today, did you use any smokeless tobacco (i.e. chewing tobacco, snuff, snus, or dissolvables)?”.
NHANES measured systolic and diastolic blood pressure three times for each participant, with a fourth
measurement being included if one of the past three attempts were incomplete. The readings were
averaged across the three measurements to produce a single measurement for analysis. It was also used
to detect the presence of hypertension, which was defined as systolic blood pressure of 130 mmHg and
above and/or diastolic blood pressure of 85 mmHg and above.
For each age cohort, Spearman correlations were observed for serum ApoB and LDL-C levels
with age (measured in years), BMI, HDL-C, triglycerides, and ItPR. Wilcoxon rank sum and Kruskal-Wallis
scores were generated for ApoB and LDL-C levels by sex, race, educational status, diabetes status,
smoking status, and presence of hypertension. All analyses were run on SAS 9.3.
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Results
Table 1. Demographic Characteristics by Age Cohort a b
Characteristics

17-80 Cohort

Age (Years)

Income-to-Poverty Ratio

Gender
Male
Female
N
N Missing (%)
Ethnicity
Non-Hispanic White
Non-Hispanic Black
Mexican-American
Other*
N
N Missing (%)
Education (Recode education)
Less than 9th Grade
9-11th Grade
High School Grad/GED
Some College/AA
College Grad
N
N Missing (%)

46 (31-62)

N = 6261
N Missing (%) =
0

N = 5761
2.02 (1.02-3.93) N Missing (%) =
500 (7.99)

2994 (47.82)
3267 (52.18)

17-50 Cohort

33 (23-42)

N = 3304
1.84 (0.91-3.82) N Missing (%) =
282 (7.86)

1716 (47.85)
1870 (52.15)
6261
0

2609 (41.67)
1292 (20.64)
879 (14.04)
1481 (23.65)

b Categorical variables: frequencies (%)

N = 2457
2.18 (1.12-4.13) N Missing (%) =
218 (8.15)

2675
0

1250 (46.73)
569 (21.27)
309 (11.55)
547 (20.45)
3586
0

160 (4.47)
676 (18.87)
822 (22.95)
1108 (30.93)
816 (22.78)
6254
7 (0.11)

N = 2675
N Missing (%) =
0

1278 (47.78)
1397 (52.22)

1359 (37.90)
723 (20.16)
570 (15.90)
934 (26.05)

463 (7.40)
1049 (16.77)
1449 (23.17)
1850 (29.58)
1443 (23.07)

64 (58-73)

3586
0

6261
0

a Continuous variables: median (IQR)

N = 3586
N Missing (%) =
0

51-80 Cohort

2675
0

303 (11.34)
373 (13.96)
627 (23.47)
742 (27.77)
627 (23.47)
3582
4 (0.11)

2672
3 (0.11)
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Table 2. Lipid Profile by Age Cohort a
Characteristics

17-80 Cohort

17-50 Cohort

N = 2759
Apolipoprotein B

87 (71-104)

N Missing (%)
= 3502 (55.93)
N = 2720

Low-density
Lipoprotein (LDL)

High-density
Lipoprotein (HDL)

107 (84.5-131) N Missing (%)
= 3541 (56.56)

50 (42-61)

N = 5769
N Missing (%)
= 492 (7.86)

84 (69-101)

N = 1514
N Missing (%)
104 (84-127)
= 2072
(57.78)

49 (41-59)

N = 3288
N Missing (%)
= 298 (8.31)

86 (58-129)

N = 1544
N Missing (%)
= 2042
(56.94)

N = 2760
Triglycerides

93 (63-141)

a Continuous variables: median (IQR)

N Missing (%)
= 3501 (55.92)

N = 1543
N Missing (%)
= 2043
(56.97)

51-80 Cohort

91 (75-106)

N = 1216
N Missing (%)
= 1459
(54.54)

111 (86-135)

N = 1206
N Missing (%)
= 1469
(54.92)

51 (42-64)

N = 2481
N Missing (%)
= 194 (7.25)

N = 1216
N Missing (%)
102 (70.5-150)
= 1459
(54.54)
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Table 3. Metabolic and Other Risk Factors by Age Cohort a b
Characteristics

17-80 Cohort

17-50 Cohort

N = 5987
27.6 (23.832.3)

Body Mass Index (kg/m3)

N Missing (%)
= 274 (4.38)

N = 3434
27.1 (23.232.0)

N = 5852
Systolic (mmHg)

119 (109-132) N Missing (%)
= 409 (6.53)

High Blood Pressure
Hypertension
No Hypertension
N
N Missing (%)
Diabetes Status
Diabetes
No Diabetes
N
N Missing (%)
Smoking Status
Ever Smoked
Never Smoked
N
N Missing (%)

69 (62-77)

N Missing (%)
= 425 (6.79)

1730 (29.56)
4122 (70.44)

115 (107-123) N Missing (%)
= 239 (6.66)

69 (62-76)

518 (15.48)
282 (84.52)

877 (14.01)
5384 (85.99)

71 (62-77)

N Missing (%)
= 183 (6.84)

2505
170 (6.36)

682 (25.50)
1993 (74.50)
3586
0

1428 (39.92
2149 (60.08)
6252
9 (0.14)

N = 2492

1212 (48.38)
1293 (51.62)

195 (5.44)
3391 (94.56)

2787 (44.58)
3465 (55.42)

129 (117-141) N Missing (%)
= 170 (6.36)

3347
239 (6.66)

6261
0

b Categorical variables: frequencies (%)

N Missing (%)
= 242 (6.75)

N Missing (%)
= 122 (4.56)
N = 2505

N = 3344

5852
409 (6.53)

a Continuous variables: median (IQR)

N Missing (%)
= 152 (4.24)

N = 2553
28.1 (24.732.7)

N = 3347

N = 5836
Diastolic (mmHg)

51-80 Cohort

2675
0

1359 (50.80)
1316 (49.20)
3577
9 (0.14)

2675
0
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Table 4. Associations Between ApoB/LDL-C and Demographic Characteristics a b
Characteristics

17-80 Cohort
ApoB

LDL-C

17-50 Cohort
ApoB

LDL-C

51-80 Cohort
ApoB

LDL-C

Age (Years)

.185 (<.0001)

.112 (<.0001)

.352 (<.0001)

.303 (<.0001)

-.187 (<.0001)

-.226 (<.0001)

Income-to-Poverty Ratio

.031 (.120)

.065 (.001)

.046 (.085)

.065 (0.015)

-.015 (.621)

.051 (.087)

Gender
Male
Female
P-value

88.0 (72.0-106.0) 106.0 (83.0-133.0)
86.0 (71.0-102.0) 107.0 (86.0-130.0)
0.019
0.546

87.0 (71.0-107.0) 107.0 (84.0-133.0)
81.0 (67.0-97.0) 101.0 (83.0-122.0)
<.0001
0.002

89.0 (73.0-105.0) 105.0 (82.0-132.0)
93.0 (76.0-107.0) 116.0 (92.0-138.0)
0.024
<.0001

Ethnicity
Non-Hispanic White
Non-Hispanic Black
Mexican-American
Other*
P-value

86.5 (72.0-103.0)
81.0 (67.0-100.0)
90.5 (75.0-109.0)
90.0 (72.0-106.0)
<.0001

106.0 (84.0-130.0)
104.0 (82.0-130.0)
108.5 (89.0-129.5)
110.0 (86.0-134.0)
0.116

85.0 (70.0-103.0)
77.0 (64.0-94.0)
89.0 (73.0-108.0)
85.0 (68.0-100.0)
<.0001

105.0 (84.0-130.0)
99.0 (80.0-124.0)
106.5 (87.0-129.0)
103.0 (84.0-125.0)
0.103

88.0 (73.0-104.0)
88.0 (72.0-101.0)
93.0 (80.0-111.0)
99.0 (82.0-111.0)
<.0001

106.0 (83.0-131.0)
110.0 (85.0-138.0)
111.5 (91.0-130.0)
121.0 (91.0-143.0)
0.001

Education (Recode education)
Less than 9th Grade
9-11th Grade
High School Grad/GED
Some College/AA
College Grad
P-value

91.0 (75.0-109.0)
85.0 (71.0-102.0)
87.0 (71.0-103.5)
87.0 (71.0-104.0)
87.0 (71.0-103.0)
0.0624

110.0 (87.0-134.0)
103.0 (81.0-128.0)
108.0 (85.0-133.0)
106.0 (85.0-129.0)
107.0 (86.0-133.0)
0.15

88.0 (73.0-109.0)
81.0 (68.0-99.0)
85.0 (68.0-103.0)
83.0 (69.0-102.0)
85.0 (68.0-100.0)
0.598

109.5 (89.0-131.0)
102.0 (80.0-121.0)
105.5 (85.0-133.0)
103.0 (84.0-126.0)
104.0 (85.0-129.0)
0.216

92.0 (76.0-111.0)
91.0 (75.0-104.0)
90.0 (75.0-104.0)
93.0 (74.0-106.0)
89.5 (73.0-107.0)
0.666

110.0 (86.0-134.0)
105.0 (83.5-135.0)
110.0 (86.0-132.0)
113.5 (87.0-134.0)
112.0 (88.0-137.0)
0.724

a Continuous variables: Spearman correlation (P-value)
b Categorical variables: Median (Interquartile Range)

Demography:
Age showed to be associated with both ApoB and LDL-C in all age cohorts. The younger cohort
demonstrated a moderate positive association with age (ApoB: r = .352, p<.0001; LDL-C: r = .303,
p<.0001) while ApoB and LDL-C showed to be negatively associated with age in the older cohort (ApoB: r
= -.187, p<.0001; LDL-C: r = -.226, p<.0001). In all cases, ApoB had a stronger association with age than
LDL-C, regardless of the direction of the association. ItPR had a significant, albeit weak, association with
LDL-C (r = .065, p=.015) among the general and younger cohort. Otherwise, ItPR showed no association
with ApoB nor with LDL-C in the older cohort.
ApoB was associated with gender in all age cohorts, while LDL-C was associated with gender in
both age groups. It is worth noting that men had significantly higher median ApoB and LDL-C levels
within the younger cohort. In the younger cohort, median ApoB and LDL-C (IQR) were 87.0 (71.0-107.0)
and 107.0 (84.0-133.0) among males and 81.0 (67.0-97.0) and 101.0 (83.0-122.0) among females,
respectively. However, this pattern is reversed in the older cohort, with women returning higher median
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ApoB and LDL-C values (IQR) of 93.0 (76.0-107.0) and 116.0 (92.0-138.0), compared to men with median
values (IQR) of 89.0 (73.0-105.0) and 105.0 (82.0-132.0), respectively. ApoB was associated with race in
all age cohorts, whereas LDL-C was only associated with race in the older cohort. African Americans
returned the lowest median ApoB values in the younger cohort, but there was less of a disparity among
their senior counterparts. In the case of LDL-C in the older generation, the “other” race category had the
highest median values out of all the levels of race. Elevated levels of ApoB were also prevalent in the
older cohort, whereas Mexican-Americans held this distinction in the younger cohort. Education was not
associated with ApoB nor LDL-C in any age category.

Table 5. Associations Between ApoB/LDL-C and Lipids a
Characteristics

17-80 Cohort
ApoB
LDL-C

17-50 Cohort
ApoB
LDL-C

51-80 Cohort
ApoB
LDL-C

High-density Lipoprotein (mg/dL)

-.224 (<.0001)

-.020 (.307)

-.284 (<.0001) -.109 (<.0001)

-.181 (<.0001)

.066 (.021)

Triglycerides (mg/dL)

.526 (<.0001)

.252 (<.0001)

.570 (<.0001)

.438 (<.0001)

.144 (<.0001)

.325 (<.0001)

a Continuous variables: Spearman correlation (P-value)

Lipids:
ApoB was negatively associated with HDL-C in all age cohorts. LDL-C was negatively associated
with HDL-C in the younger cohort (r = -.109, p<.0001), while the older cohort showed a weak positive
association (r = .066, p=.021). In all instances, ApoB presented a stronger association than LDL-C with
HDL-C. Triglycerides were associated with both ApoB and LDL-C in every age category. Once again, ApoB
had a far stronger correlation with triglycerides than LDL-C in all cohorts.
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Table 6. Associations Between ApoB/LDL-C and Metabolic and Other Risk Factors a b
17-80 Cohort
ApoB

Characteristics

Body Mass Index (kg/m3).229 (<.0001)

LDL-C

17-50 Cohort
ApoB

LDL-C

51-80 Cohort
ApoB

LDL-C

.128 (<.0001)

.332 (<.0001)

.246 (<.0001)

.056 (.054)

-.039 (.176)

Diabetes Status
Diabetes
No Diabetes
P-value

88.0 (72.0-105.0) 98.0 (75.0-122.0)
87.0 (71.0-103.0) 108.0 (87.0-132.0)
0.152
<.0001

93.0 (76.0-120.0) 101.0 (82.0-125.0)
83.0 (68.0-100.0) 104.0 (84.0-127.0)
0.0001
0.857

86.5 (71.0-101.0) 96.5 (73.5-120.0)
92.0 (76.0-107.0) 115.0 (91.0-138.0)
0.003
<.0001

Smoking Status
Ever Smoked
Never Smoked
P-value

88.0 (72.0-106.0) 105.0 (83.0-132.0)
86.0 (71.0-102.0) 107.0 (86.0-130.0)
0.036
0.545

87.0 (71.0-105.0) 105.0 (84.0-130.0)
81.0 (68.0-100.0) 103.0 (83.0-125.0)
0.0007
0.139

90.0 (72.0-106.0) 106.0 (82.0-133.0)
92.0 (77.0-106.0) 115.0 (90.0-137.0)
0.122
0.003

Blood Pressure
Systolic (mmHg)
Diastolic (mmHg)

.172 (<.0001)
.201 (<.0001)

.201 (<.0001)
.249 (<.0001)

.051 (.078)
.132 (<.0001)

High Blood Pressure
Hypertension
No Hypertension
P-value

92.0 (74.0-109.0) 109.0 (87.0-136.0)
85.0 (70.0-102.0) 105.0 (83.0-129.0)
<.0001
0.001

.107 (<.0001)
.167 (<.0001)

.132 (<.0001)
.187 (<.0001)

91.0 (72.0-111.0) 109.0 (87.0-136.0)
82.0 (68.0-99.0) 103.0 (83.0-125.0)
<.0001
0.006

.032 (.280)
.136 (<.0001)

92.0 (74.5-107.0) 109.0 (87.0-136.0)
90.0 (75.0-105.0) 113.0 (85.5-134.0)
0.2572
0.592

a Continuous variables: Spearman correlation (P-value)
b Categorical variables: Median (Interquartile Range)

Metabolic and Other Risk Factors:
Body mass index was associated with both ApoB and LDL-C in the younger groups, but not in the
older cohort. As has been the case with other variables, ApoB demonstrated a stronger association with
BMI (r=.332, p<.0001) than LDL-C (r=.246, p<.0001) in the younger cohort.
Diabetes status was associated with ApoB in the younger and older generation, whereas it was
associated with LDL-C only in the older cohort. Smoking status was associated with ApoB in the younger
cohort and with LDL-C in the older cohort. Systolic and diastolic blood pressure, measured as continuous
variables, were associated with both ApoB and LDL-C in all age groups, except for systolic pressure in the
older cohort. As for the presence of hypertension, both ApoB and LDL-C were associated with high blood
pressure in the general and younger cohort. Hypertension seemed to have no influence on the variables
of interest in the older generation.
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Discussion and Conclusion
The aim of this study was to examine the distribution of ApoB and LDL-C across age groups and
determine if ApoB demonstrated greater sensitivity to cardiovascular risk factors, as previous research
has suggested. The general trend reinforced in our findings points towards ApoB acting as a more
sensitive biomarker in relation to cardiovascular risk factors than LDL-C, mainly in the 17-50 cohort. All
variables in which ApoB and LDL-C were both statistically significant in the younger cohort consistently
revealed stronger associations with ApoB than LDL-C. In the senior cohort, the trends attenuated, and
unlike their younger counterparts, if ApoB proved to be statistically significant, then LDL-C did, as well.
ApoB does not seem to have a special relationship with risk factors in older age as it does with the
young.
In addition, various risk factors demonstrated differential associations based on age. Race,
diabetes status, and smoking status in particular were associated with serum ApoB in the younger
cohort, but showed no statistically significant association with LDL-C. Conversely, race and diabetes
status were associated with both ApoB and LDL-C in the older group. Hypertension, as defined in this
study, also generated differential results based on age, with both ApoB and LDL-C responding stronger
to high blood pressure (categorically and continuously) in younger adults than older adults.
Differences in lipoprotein distribution were evident between gender, race, and diabetes status.
Whatever patterns found in the young were reversed in older age. The most plausible explanation of
this phenomena could be attributed to the general pattern of mortality in old age. Higher risk groups
present among the young could have died as age progressed, skewing the present distribution of
lipoproteins among the senior population. As this study is cross-sectional in nature, we cannot account
for risk over time nor can we come to conclusions about cardiovascular risk. Instead, we have sought to
understand the relationship between lipoprotein biomarkers and cardiovascular risk factors.
Cardiovascular risk in particular cannot be quantified nor qualified by a single factor. Rather, risk can be
additive or even multiplicative.
Bachorik and colleagues (1997) highlight that ApoB and LDL-C follow a stepwise pattern of
distribution across age, and that should be of particular concern when it comes to clinical practice.
These lipoproteins mirror each other in trend – ApoB does indeed follow LDL-C. However, as our study
shows, ApoB’s amplified sensitivity to cardiovascular risk factors among the young falls in line with much
of the recent consensus regarding ApoB’s more sensitive role in CVD risk assessment and prevention
efforts than LDL-C.
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Strengths of our study include the large study population of adults with diverse demographic
and metabolic characteristics. This allowed us to examine multiple facets of the association between
ApoB, LDL-C, and cardiovascular risk factors. Weak points within this study center on its cross-sectional
nature. Since we cannot follow-up with the subjects, we cannot deduce incidence nor actual risk.
Moreover, we did not include information regarding lipid-lowering medication use in analysis due to a
high proportion of missing values (not indicated in the tables). While this is a detriment, especially
concerning the elderly, our findings are still germane in the context our aims, notwithstanding of the
influence of medication. Future research efforts would certainly benefit from data concerning statin-use
and other lipid-lowering prescriptions.
In brief, ApoB seems to have a special relationship with the younger cohort that does not
manifest with LDL-C, and this relationship disappears in the older cohort. While the scope of this study
does not allow us to make definitive conclusions as to the predictive ability of ApoB concerning CVD and
CVD events, we have reason to believe that the assessment of CVD risk among the young would benefit
from including ApoB in the already established battery of biomarkers.
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